Method for preventing ketamine crystallization
Filtration and pH adjustment in ketamine solutions with specific membrane pore sizes and container volumes prevent crystallization, ensuring stable ketamine formulations for nasal administration.
Patent Information
- Application Number
- PCT/DK2026/060059
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Crystallization of ketamine occurs in liquid formulations, particularly at lower temperatures, affecting the dosage and uptake of active ingredients like esketamine, which is hard to detect and has not been adequately addressed.
A method involving filtration through a membrane with a nominal pore size of less than 0.40 μm, adjusting the pH to 4.1 - 5.1, and storing the solution in a container with a volume of less than 1.0 ml, specifically for nasal sprays, to prevent crystallization of esketamine or its pharmaceutically acceptable salts.
The method significantly reduces crystallization, maintaining storage stability for up to 36 months, allowing for effective administration and treatment of conditions like cluster headache without crystalline interference.
Smart Images

Figure DK2026060059_12112026_PF_FP_ABST
Abstract
Description
[0001] 10337 / PC
[0002] Method for Preventing Ketamine Crystallization The present invention relates to a method for preventing crystallization in a solution comprising ketamine. In particular, the method concerns a method for increasing the storage stability of a pharmaceutical composition comprising ketamine for nasal administration.
[0003] Technical Background
[0004] The International patent application WO 2020 / 240279 discloses a pharmaceutical composition comprising ketamine for the treatment of cluster headache.
[0005] The European patent application EP 4501314 Al describes a method for making an R-ketamine liquid formulation for nasal administration for the treatment of depression. The US patent application US 2025 / 0025431 Al describes a method for making an aqueous ketamine solution for intravenous infusion to a subject in need of anesthesia.
[0006] Summary of the invention
[0007] Liquid pharmaceutical ketamine formulations, such as nasal sprays, are commercially available. The inventors of the present invention have surprisingly discovered that crystallization of ketamine may occur in liquid ketamine formulations. The inventors have discovered that crystallization of ketamine in aqueous solution becomes pronounced upon storage, in particular when the temperature is decreased, such as at temperatures lower than room temperature. This problem may not have been fully appreciated before because crystallization may lead to very small crystals which are hard to detect.
[0008] The inventors of the present invention have further discovered that the problem with crystallization of ketamine is pronounced when using the active ingredient esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof, such as esketamine hydrochloride. It is desirable that crystallization is prevented in liquids, such as solutions or aqueous compositions, comprising or constituting pharmaceutical formulations. In particular, it is desirable to prevent crystallization in aqueous compositions comprising ketamine for use as a pharmaceutical composition, such as a nasal spray. Crystallization of an active ingredient,10337 / PC
[0009] such as ketamine, may affect the amount of active ingredient and thus the dosage of the active ingredient contained in a specific volume of the liquid. Without being bound by theory, it is further speculated that crystallization may affect uptake of the active ingredient after administration.
[0010] Crystallization in a ketamine solution may be hard to detect, and it may be speculated that hitherto this problem has not received appropriate attention, and may not have been addressed fully.
[0011] Aspects of the present invention are provided in the claims.
[0012] According to an aspect the invention concerns a method for making a solution comprising ketamine, comprising a step of filtration.
[0013] According to another aspect, the invention concerns a solution or composition obtainable according to a method of the invention.
[0014] According to another aspect, the invention concerns a container comprising a solution or composition according to the invention.
[0015] According to another aspect, the invention concerns a nasal spray comprising the pharmaceutical composition according to the invention.
[0016] According to another aspect, the invention concerns a ketamine nasal spray comprising a container, said container comprising a storage stable aqueous solution of ketamine, wherein said aqueous solution of ketamine has a volume of less than 1.0 ml, said aqueous solution of ketamine being obtainable by micro filtration using a filter or membrane having a nominal pore size of less than 0.40 pm; and wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof.
[0017] According to another aspect, the invention concerns a method for preparing a storage stable ketamine solution for a nasal spray, wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof, said method comprising: Filtration of an aqueous solution of ketamine using a filter or membrane having a nominal pore size of less than 0.40 pm; Adjusting the pH, preferably to a pH of 4.1 - 5.1; and Filling said aqueous solution in a container for a nasal spray, wherein the volume of said aqueous solution is less than 1.0 ml.10337 / PC
[0018] According to another aspect, the invention concerns a method for decreasing the amount of crystallized ketamine or preventing crystallization of ketamine in an aqueous solution in a nasal spray, wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof, wherein said method comprises: Filtration of an aqueous solution of ketamine using a filter or membrane having a nominal pore size of less than 0.40 pm;
[0019] Adjusting the pH, preferably to a pH of 4.1 - 5.1; and Subsequent storage of said aqueous solution in a container for a nasal spray, wherein the volume of said aqueous solution is less than 1.0 ml.
[0020] According to another aspect, the invention concerns a method for the treatment of cluster headache comprising administration of a solution according to the invention, and / or administration using a nasal spray according to the invention.
[0021] Detailed Disclosure
[0022] Embodiments of the present invention are provided in the claims.
[0023] According to an embodiment, the invention concerns a method for making a solution comprising ketamine, comprising a step of filtration.
[0024] According to an embodiment, the invention concerns the method for increasing the storage stability of a solution or composition comprising ketamine.
[0025] According to an embodiment, the invention concerns the method for decreasing the propensity of ketamine to crystallize in an aqueous solution.
[0026] According to an embodiment, the invention concerns the method, wherein said step of filtration prevents crystallization.
[0027] According to an embodiment, crystallization may be detected by measuring the weight of a solution before and after filtration and comparing the two measurements.
[0028] According to an embodiment, crystallization may be detected by quantification of ketamine before and after filtration or microfiltration and comparing the results.
[0029] According to an embodiment crystallization of the solution may be assessed in the following ways for comparison:10337 / PC
[0030] i) Ketamine is quantified after sterile filtration to exclude potential precipitation of ketamine crystals.
[0031] ii) Crystals are dissolved by increasing the temperature to 40 °C and stirring the solution until all crystals are dissolved by visual examination. Then ketamine is quantified. Subsequently, the two results, i) and ii), are compared to determine the degree of crystallization, and the effect of sterile filtration.
[0032] According to another embodiment, crystallization may be detected by visual inspection. According to an embodiment, the invention concerns the method, wherein the step of filtration reduces the presence of seeds for precipitation.
[0033] According to an embodiment, the invention concerns the method, wherein the step of filtration comprises microfiltration.
[0034] According to an embodiment, the invention concerns the method, wherein the step of filtration comprises microfiltration, wherein said microfiltration comprises a pressure-driven separation process.
[0035] According to an embodiment, the invention concerns the method, wherein the step of filtration comprises filtration using a filter or membrane having a nominal pore size of 0.01 -10 pm, preferably 0.025 - 5 pm, more preferred 0.05 - 2 pm, preferably 0.1 - 1.0 pm, more preferred 0.125 - 0.5 pm, preferably 0.15 -0.45 pm, more preferred 0.18 - 0.4 pm, preferably 0.2 - 0.25 pm, more preferred 0.22 pm.
[0036] According to an embodiment, the invention concerns the method, wherein the step of filtration comprises filtration using a filter or membrane having a nominal pore size of 0.01 -0.39 pm, preferably 0.025 - 0.37 pm, more preferred 0.05 - 0.34 pm, preferably 0.1 - 0.31 pm, more preferred 0.1 - 0.28 pm, preferably 0.2 - 0.25 pm, more preferred 0.22 pm.
[0037] According to an embodiment, the invention concerns the method, wherein the step of filtration comprises filtration using a 0.22 pm membrane or filter.
[0038] According to an embodiment, the invention concerns the method, wherein the filtration is sterile filtration.10337 / PC
[0039] According to an embodiment, the invention concerns the method, wherein the method prevents crystallization below 10°C, preferably below 8°C, more preferred below 6°C, preferably below 4°C, more preferred below 2°C.
[0040] According to an embodiment, the invention concerns the method, wherein the method prevents crystallization in a temperature interval selected among 0 - 10°C, 1 - 9°C, 2 - 8°C, 3 -7°C, 4 - 6°C, and preferably about 5°C.
[0041] According to an embodiment, the invention concerns the method, wherein the method prevents crystallization for at least 1 month, more preferred at least 2 months, preferably at least 3 months, more preferred at least 4 months, preferably at least 5 months, more preferred at least 6 months, preferably at least 8 months, more preferred at least 10 months, preferably at least 12 months, more preferred at least 15 months, preferably at least 18 months, more preferred at least 24 months, preferably at least 30 months, more preferred at least 36 months.
[0042] According to an embodiment, the invention concerns the method, wherein the concentration of ketamine is selected among 10 - 500 mg / mL, preferably 25 - 300 mg / mL, more preferred 50 - 200 mg / mL, preferably 75 - 175 mg / mL, and more preferred 100 - 150 mg / mL.
[0043] According to an embodiment, the invention concerns the method, wherein the solution is an aqueous solution.
[0044] According to an embodiment, the invention concerns the method, wherein the solution comprises a buffer.
[0045] According to an embodiment, the invention concerns the method, wherein the buffer comprises one or more excipients selected among citric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium hydroxide, acetic acid, boric acid, sodium borate, succinic acid, tartaric acid, malic acid, lactic acid, fumaric acid, and the like. Preferably, the buffer or buffer system is selected from the group consisting of sodium hydroxide, citric acid, sodium dihydrogen phosphate and disodium hydrogen phosphate.
[0046] According to an embodiment, the invention concerns the method, wherein the buffer comprises a phosphate buffer.10337 / PC
[0047] According to an embodiment, the invention concerns the method, wherein the buffer comprises a citrate buffer.
[0048] According to an embodiment, the invention concerns the method, wherein the method comprises a step of adjusting the pH of the solution.
[0049] According to an embodiment, the invention concerns the method, wherein the pH is adjusted to an interval selected among 2.5 - 6.5; 2.6 - 6.4; 2.7 - 6.3; 2.8 - 6.2; 2.9 - 6.1; 3.0 -6.0; 3.1 - 5.9; 3.2 - 5.8; 3.3 - 5.7; 3.4 - 5.6; 3.5 - 5.5; 3.6 - 5.4; 3.7 - 5.3; 3.8 - 5.2; 3.9 - 5.1; 4.0 -5.0; 4.1 - 4.9; 4.2 - 4.8; 4.3 - 4.7; 4.4 - 4.6; 4.5 - 4.6; and about 4.6.
[0050] According to an embodiment, the invention concerns the method, wherein the pH is adjusted by adding sodium hydroxide and / or hydrochloric acid to the solution.
[0051] According to an embodiment, the invention concerns the method, wherein the solution comprises one or more excipients selected among EDTA and disodium-EDTA.
[0052] According to an embodiment, the invention concerns the method, wherein the ketamine is esketamine.
[0053] According to an embodiment, the invention concerns the method, wherein the ketamine is esketamine hydrochloride.
[0054] According to an embodiment, the invention concerns the method, wherein the method comprises a step of filtration of a solution comprising the buffer and / or a solution comprising ketamine.
[0055] According to an embodiment, the invention concerns the method, wherein the solution comprising ketamine is a pharmaceutical composition.
[0056] According to an embodiment, the invention concerns the method for manufacturing a nasal spray comprising ketamine.
[0057] According to an embodiment, the invention concerns the method for increasing the propensity of ketamine to redissolve in an aqueous solution, in particular when moved from cold storage to room temperature.
[0058] According to an embodiment, the invention concerns the method for increasing the rate of redissolving ketamine crystals in an aqueous solution when moved from cold storage to room temperature.10337 / PC
[0059] According to an embodiment, the invention concerns the method for increasing the propensity of ketamine to redissolve in an aqueous solution when moved from cold storage to room temperature storage wherein cold storage is storage in a temperature interval selected among 0 - 10°C, 1 - 9°C, 2 - 8°C, 3 - 7°C, 4 - 6°C, and preferably about 5°C.
[0060] According to an embodiment, the invention concerns a method for preparing a storage stable ketamine solution for a nasal spray, wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof, said method comprising: Filtration of an aqueous solution of ketamine using a filter or membrane having a nominal pore size of less than 0.40 pm; Adjusting the pH, preferably to a pH of 4.1 - 5.1; and Filling said aqueous solution in a container for a nasal spray, wherein the volume of said aqueous solution is less than 1.0 ml.
[0061] According to an embodiment, the invention concerns a method for decreasing the amount of crystallized ketamine or preventing crystallization of ketamine in an aqueous solution in a nasal spray, wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof, wherein said method comprises: Filtration of an aqueous solution of ketamine using a filter or membrane having a nominal pore size of less than 0.40 pm;
[0062] Adjusting the pH, preferably to a pH of 4.1 - 5.1; and Subsequent storage of said aqueous solution in a container for a nasal spray, wherein the volume of said aqueous solution is less than 1.0 ml.
[0063] According to an embodiment, the invention concerns the method for manufacturing a nasal spray comprising an aqueous solution of ketamine, wherein said nasal spray allows cooling to a temperature below 10°C and subsequently heating to room temperature before use, to obtain a nasal spray which does not comprise crystallized ketamine after said heating to room temperature.
[0064] According to an embodiment, the invention concerns the method, wherein said nasal spray allows cooling to a temperature in a temperature interval selected among 0 - 10°C, 1 - 9°C, 2 - 8°C, 3 - 7°C, 4 - 6°C, and about 5°C, and subsequently heating to room temperature, such as 20°C, before use, to obtain a nasal spray which does not comprise crystallized ketamine after said heating to room temperature.10337 / PC
[0065] According to an embodiment, the invention concerns the method, wherein said nasal spray allows cooling to a temperature below 10°C and subsequently heating to room temperature, before use, to obtain a nasal spray which does not comprise crystallized ketamine at a time selected among 1 min - 24 hours, preferably 5 min - 20 hours, more preferred 15 min - 16 hours, preferably 30 min - 12 hours, more preferred 1 - 10 hours, preferably 2 - 8 hours, more preferred 3 - 6 hours, preferably 4 - 5 hours, after said heating to room temperature. According to an embodiment, the invention concerns the method, wherein the method prevents crystallization in a temperature interval selected among 0 - 10°C, 1 - 9°C, 2 - 8°C, 3 -7°C, 4 - 6°C, and preferably about 5°C.
[0066] According to an embodiment, the invention concerns a solution or composition obtainable according to the method of the invention.
[0067] According to an embodiment, the invention concerns the solution or composition, wherein the solution or composition is a pharmaceutical composition.
[0068] According to an embodiment, the invention concerns a ketamine nasal spray comprising a container, said container comprising a storage stable aqueous solution of ketamine, wherein said aqueous solution of ketamine has a volume of less than 1.0 ml, said aqueous solution of ketamine being obtainable by micro filtration using a filter or membrane having a nominal pore size of less than 0.40 pm; and wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof.
[0069] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein said pharmaceutically acceptable salt is esketamine hydrocholoride. According to an embodiment, the invention concerns the nasal spray according to the invention, wherein said nasal spray allows cooling to 2 - 8 °C without formation of ketamine crystals.
[0070] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein said nasal spray allows cooling to 2 - 8 °C and storage at a temperature of 2 - 8 °C, and subsequent use at a temperature higher than 10°C without formation of ketamine crystals.10337 / PC
[0071] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein said solution of ketamine has been adjusted to having a pH of 4.1 - 5.1. According to an embodiment, the invention concerns the nasal spray according to the invention, further comprising EDTA.
[0072] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein the volume of said aqueous solution of ketamine is selected among 0.01 -0.99; 0.02 - 0.9; 0.03 - 0.8; 0.04 - 0.7; 0.05 - 0.6; 0.06 - 0.5; 0.07 - 0.4; 0.08 - 0.3; 0.09 - 0.2; 0.1 - 0.15; and 0.125 ml, preferably about 0.125 ml.
[0073] According to an embodiment, the invention concerns a container comprising a solution or composition according to or obtainable according to the invention.
[0074] According to an embodiment, the invention concerns the container, wherein said container has an inner surface, wherein the part of said inner surface being in contact with said solution or composition, is made of glass, such as borate or silicate glass.
[0075] According to an embodiment, the invention concerns the container, comprising an inner part having a surface with a coefficient of thermal expansion lower than a value selected among 10 * 10'5K1, 9 * 10'5K1, 8 * 10'5K1, 7 * 10'5K1, 6 * 10'5K1, 5 * 10'5K1, 4 * 10'5K1, 3 * 10'5K1, 2 * IO-5K1, and 1 * IO-5K1at 20 °C.
[0076] Without being bound by theory the inventors of the present invention speculate that materials such as glasses with very low coefficients of thermal expansion may provide a stable environment for a ketamine solution, contributing to a low tendency to form crystals. According to an embodiment, the invention concerns the container, wherein said container has a volume selected among < 2 ml, < 1 ml, < 0.5 ml or < 0.25 ml
[0077] According to an embodiment, the invention concerns the container, wherein said container has a volume selected among 0.01 - 2; 0.02 - 1.5; 0.03 - 1.25; 0.04 - 1; 0.05 - 0.75; 0.06 - 0.5; 0.07 - 0.4; 0.08 - 0.3; 0.09 - 0.25; 0.1 - 0.15; and 0.125 ml.
[0078] According to an embodiment, the invention concerns the container, wherein said container has a volume of 0.125 ml.10337 / PC
[0079] Without being bound by theory the inventors of the present invention speculate that a small volume of the container may provide a more stable environment for a ketamine solution, contributing to a low tendency to form crystals.
[0080] According to an embodiment, the invention concerns the nasal spray comprising a pharmaceutical composition according to the invention, such as an aqueous solution comprising ketamine.
[0081] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein the nasal spray comprises a container which does not promote crystallization of ketamine.
[0082] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein the nasal spray comprises a container, wherein said container is made of plastic and / or glass.
[0083] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein the nasal spray comprises a container, wherein said container is made of borosilicate, borate, silicate glass or soda-lime glass.
[0084] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein the nasal spray comprises a container, wherein said container has a color, a coating or a surface which protects the solution from light.
[0085] According to an embodiment, the invention concerns the nasal spray according to the invention, wherein the nasal spray comprises a container, wherein said container has a color, a coating or a surface which protects the pharmaceutical composition from light.
[0086] According to an embodiment, the invention concerns a method for the treatment of cluster headache comprising administration of a solution according to the invention, and / or administration using a nasal spray according to the invention.
[0087] According to an embodiment, the method comprises a filtration step in the manufacturing of a pharmaceutical formulation comprising ketamine.
[0088] According to an embodiment, the invention concerns a method of treating patients with cluster headache comprising intranasal administration to a patient in need thereof of a liquid10337 / PC
[0089] composition, such as an aqueous composition, comprising a therapeutically effective amount of ketamine, i.e. an amount effective to treating said cluster headache.
[0090] Another embodiment is a composition, e.g., a pharmaceutical composition, comprising a therapeutically effective amount of ketamine for use in the treatment of cluster headache, wherein the composition is in a nasal dosage form.
[0091] According to an embodiment of the invention a composition of the invention may be in the form of nasal spray or nasal drops.
[0092] According to an embodiment of the invention, a composition of the invention comprises ketamine as the only active pharmaceutical ingredient.
[0093] According to an embodiment of the invention, a composition of the invention comprises ketamine as the only active pharmaceutical ingredient for the treatment of cluster headache, such as chronic cluster headache and / or episodic cluster headache.
[0094] According to an embodiment of the invention a nasal spray of the invention may be a one use device comprising a number of doses selected among 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 doses. According to an embodiment of the invention the active pharmaceutical ingredient (API) is ketamine. According to an embodiment the ketamine is selected from the group consisting of the hydrochloride salts of (R,S)-ketamine and S-ketamine.
[0095] According to an embodiment of the invention the therapeutically effective amount of ketamine may be at least 5 mg, or at least 10 mg, or at least 15 mg of ketamine base (2-2(chlorophenyl)-2-(methylamino)cyclohexanone), delivered in a single dose or unit dose. In a further embodiment, the therapeutically effective amount of ketamine is not higher than about 150 mg, or not higher than about 100 mg, or not higher than about 75 mg, or not higher than about 50 mg of ketamine base (2-2(chlorophenyl)-2-(methylamino)cyclohexanone), delivered in a single dose or unit dose.
[0096] A composition of the invention may be used for the treatment of a person suffering from Cluster headache (CH), such as selected among chronic CH and episodic CH.
[0097] As used herein, unless otherwise noted, the terms "S-ketamine" and "S ketamine hydrochloride" shall mean the (S)-enantiomer of ketamine, also known as esketamine, and10337 / PC
[0098] its corresponding hydrochloride salt, a compound known as (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
[0099] As used herein, unless otherwise noted, the term "ketamine" (2-(2-chlorophenyl)-2-(methylamino)cyclohexanone) shall mean any of R,S-ketamine, R,S-ketamine hydrochloride, S-ketamine, S-ketamine hydrochloride, R-ketamine, R-ketamine hydrochloride.
[0100] As used herein, the amount of ketamine present in a composition, e.g., pharmaceutical composition, of the invention refers to the weight / molecular weight of the ketamine base (2-(2-chlorophenyl)-2-(methylamino)cyclohexanone). The weight / molecular weight ratio of the hydrochloride salt of ketamine to that of the ketamine base is 1.15.
[0101] The hydrochloride salt of ketamine is water-soluble and has a pKa of 7.5. Two enantiomers exist: S-(+)-ketamine and R-(-)-ketamine. The pharmacological activity of the S-(+) enantiomer is up to two to three times higher than of the R-(-) enantiomer. Ketamine is a white or almost white crystalline powder. Ketamine is freely soluble in water (1:4) and in methyl alcohol; and is soluble in alcohol. A 10% aqueous solution has a pH of between 3.5 and 4.1.
[0102] The term "pharmaceutical composition" includes any pharmaceutical preparation or formulation that is customized for being administered to a human being or animal.
[0103] According to an embodiment, a composition of the invention contains one or more physiologically acceptable carriers and / or excipients. According to an embodiment, a pharmaceutical composition of the invention contains water.
[0104] As used herein, unless otherwise noted, the term "aqueous" shall mean that the primary liquid component of a formulation is water. Preferably, water constitutes more than about 80 wt % of the liquid component of an aqueous composition, more preferably more than about 90 wt %, more preferably more than about 95 wt %, more preferably about 98 wt % of an aquous composition of the invention.
[0105] According to an embodiment of the invention, to prepare a composition, ketamine hydrochloride as the active pharmaceutical ingredient is intimately admixed with a pharmaceutical carrier, preferably water, according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration. Suitable pharmaceutically acceptable10337 / PC
[0106] carriers are well known in the art. Descriptions of these pharmaceutically acceptable carriers may be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.
[0107] According to an embodiment a composition of the invention is an aqueous formulation comprising water and ketamine, wherein ketamine is present in an amount in the range of from about 50 mg / mL to about 200 mg / mL, or any amount or range therein, based on the total volume of the composition. Preferably, ketamine is present in an amount in the range of from about 50 mg / mL to about 150 mg / mL, or any amount or range therein. More preferably, ketamine is present in an amount in the range of from about 150 mg / mL to about 175 mg / mL, or any amount or range therein. Even more preferably, ketamine is present in an amount in the range of from about eq. 100 mg / mL to about eq. 200 mg / mL, or any amount or range therein, based on the total volume of the composition.
[0108] According to an embodiment a composition of the invention may comprise one or more buffers and / or buffer systems (i.e. conjugate acid / base pairs).
[0109] As used herein, the term "buffer" shall mean any solid or liquid composition (preferably an aqueous, liquid composition) which, when added to an aqueous formulation, adjusts the pH of said formulation. The skilled person will recognize that a buffer may adjust the pH of the aqueous formulation in any direction (toward more acidic, more basic or more neutral pH). Preferably, the buffer is a pharmaceutically acceptable buffer.
[0110] According to an embodiment of the invention examples of buffers which may be used in the compositions disclosed herein include, but are not limited to, citric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium hydroxide, acetic acid, boric acid, sodium borate, succinic acid, tartaric acid, malic acid, lactic acid, fumaric acid, and the like.
[0111] Preferably, the buffer or buffer system is selected from the group consisting of sodium hydroxide, citric acid, sodium dihydrogen phosphate and disodium hydrogen phosphate. According to an embodiment of the invention the buffer is selected to adjust the pH of the composition into a pH in the range of from about pH 3.5 to about pH 6.5 or any amount or range therein, preferably from about pH 4.0 to about pH 5.5 or any amount or range therein, more preferably from about pH 4.5 to about pH 5.0 or any amount or range therein.10337 / PC
[0112] Preferably, the concentration of the buffer and buffer system, respectively, preferably sodium hydroxide (NaOH), is used to adjust the pH.
[0113] According to an embodiment, a composition of the invention comprises ketamine hydrochloride, water, and a buffer or buffer system, preferably comprising NaOH, wherein the buffer or buffer system is present in an amount sufficient to provide a pH in the composition in the range of from about pH 4.0 to about pH 6.0, or any amount or range therein.
[0114] According to an embodiment, a composition of the invention may comprise a preserving agent or preservative.
[0115] As used herein, unless otherwise noted, the terms "antimicrobial preservative" and "preservative" shall mean any substance conventionally used in compositions, such as pharmaceutical compositions, in order to preserve them against microbial degradation or microbial growth. In this regard, microbial growth typically plays an essential role, i.e. the preservative serves the main purpose of avoiding microbial contamination. As a side aspect, it may also be desirable to avoid any effect of the microbes on the active ingredients and excipients respectively, i.e. to avoid microbial degradation.
[0116] According to an embodiment of the invention representative examples of preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzoic acid, sodium benzoate, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorbutanol, chlorocresol, chloroxylenol, cresol, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, sodium propionate, thimerosal, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, isobutyl paraben, benzyl paraben, sorbic acid, and potassium sorbate.
[0117] According to an embodiment a composition, e.g., a pharmaceutical composition, of the invention is free of preservatives. According to this embodiment the content of ketamine or ketamine hydrochloride present in the composition is adequate for achieving the desired shelf life or in use stability due to the preservative property of the API as such.
[0118] As used herein, the terms "penetration agent", "penetration enhancer", and "penetrant" refer to any substance that increases or facilitates absorption and / or bioavailability of the active ingredient ketamine hydrochloride. Preferably, a useful penetration agent increases10337 / PC
[0119] or facilitates absorption and / or bioavailability of ketamine through the mucous membrane after nasal administration.
[0120] According to an embodiment of the invention suitable penetrating agents include, but are not limited to, tetradecyl maltoside, sodium glycocholate, lecithin, chitosan and salts thereof, and surface active ingredients such as benzalkonium chloride, sodium dodecyl sulfate and sodium docusate.
[0121] According to an embodiment a composition of the invention may comprise an absorption enhancer, such as chitosan.
[0122] According to an embodiment a composition of the invention may comprise a bioadhesive agent, such as a poloxamer.
[0123] According to an embodiment, intranasal administration of a composition of the invention is carried out by administering nose drops comprising the composition or by nasal spray comprising the composition. The nasal spray is preferably a one-dose container type comprising up to 50 mg or 75 mg of S-ketamine, preferably as the hydrochloride salt. The nasal spray may be manually activated and typically dosing 5-10 mg of S-ketamine per spray in the nostril, typically corresponding to 50-100 pL of the composition. The patient is administering one spray in a nostril repeatedly at certain time intervals, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20 or 30 minutes, preferably until headache relief is obtained. According to an embodiment a composition of the invention in a nasal spray or as nose drops may contain a local anesthetic, e.g. lidocaine, in order to suppress local pain or discomfort due to the delivery of ketamine in the nose.
[0124] According to an embodiment, tendency of the solution to crystallize is delayed and / or reduced when one or more of the following conditions are fulfilled:
[0125] the pH is adjusted to an interval selected among 2.5 - 6.5; 2.6 - 6.4; 2.7 - 6.3; 2.8 - 6.2; 2.9 -6.1; 3.0 - 6.0; 3.1 - 5.9; 3.2 - 5.8; 3.3 - 5.7; 3.4 - 5.6; 3.5 - 5.5; 3.6 - 5.4; 3.7 - 5.3; 3.8 - 5.2; 3.9 -5.1; 4.0 - 5.0; 4.1 - 4.9; 4.2 - 4.8; 4.3 - 4.7; 4.4 - 4.6; 4.5 - 4.6; and about 4.6; and / or the solution is filtered using a filter or membrane having a nominal pore size of 0.01 - 10 pm, preferably 0.025 - 5 pm, more preferred 0.05 - 2 pm, preferably 0.1 - 1.0 pm, more preferred 0.15 - 0.45 pm, preferably 0.2 - 0.25 pm, more preferred 0.22 pm; and / or10337 / PC
[0126] the solution is stored in a temperature interval selected among 0 - 10°C, 1 - 9°C, 2 - 8°C, 3 -7°C, 4 - 6°C, and preferably about 5°C; and / or
[0127] the solution is stored in a < 1 mL container, preferably a <0.5 mL container, more preferable a <0.250 mL container, preferably a 0.125 mL container.
[0128] Figures
[0129] Fig. 1 shows results of FTIR (Fourier transform infrared spectroscopy) spectra of the precipitated crystals from a phosphate buffer formulation that were isolated, dried, and compared with untreated Esketamin-HCl.
[0130] Fig. 2 shows droplet size distribution of formulation F032-SOL-A-2410-002-05 with an actuation force of 40 N, a spray angle of 45 ° and a distance of nozzle and laser beam of 30 mm.
[0131] Fig 3. Shows the redissolving of crystals as disclosed in example 7, for a ketamine composition with EDTA after relocation from 2-8°C to room temperature storage. Vials have volumes of 125 microliters (Aptar) and 2-3 mL (borosilicate Carl Roth and lime soda).
[0132] Fig 4. Shows the redissolving of crystals as disclosed in example 7, for a ketamine composition without EDTA after relocation from 2-8°C to room temperature storage. Vials have volumes of 125 microliters (Aptar) and 2-3 mL (borosilicate Carl Roth and lime soda).
[0133] All cited references are incorporated by reference.
[0134] The accompanying Figures and Examples are provided to explain rather than limit the present invention. It will be clear to the person skilled in the art that aspects, embodiments, claims and any items of the present invention may be combined.
[0135] Unless otherwise mentioned, all percentages are in weight / weight. Unless otherwise mentioned, all measurements are conducted under standard conditions (ambient temperature and pressure). Unless otherwise mentioned, test conditions are according to European Pharmacopoeia 8.0.10337 / PC
[0136] Examples
[0137] Example 1: Storage of a phosphate buffer formulation in soda lime bulk glass pH 5.3 A phosphate buffer formulation as shown in table 1 was provided for a short-term stability study:
[0138] Table 1: Formulation (F032-SOL-A-2407-001-01)
[0139] Substance Function Content [%] Esketamine hydrochloride API 17.3
[0140] Disodium hydrogen Buffer 0.181
[0141] phosphate, dihydrate
[0142] Sodium dihydrogen Buffer 1.131
[0143] phosphate, dihydrate
[0144] Sodium hydroxide pH adjustment ad pH 6
[0145] Hydrochloric acid pH adjustment ad pH 6
[0146] Water for injection Solvent ad 100
[0147]
[0148] For the manufacturing the buf er was prepared, and API was added, which dissolved rapidly. To evaluate stability of the formulation, three storage conditions were tested over a shortterm stability study: 2-8 °C, Room temperature (RT) and 40 °C. The solution was tested initially, after 4 and 8 weeks. The results for the formulation stored at 2-8 °C are shown in table 2.
[0149] Table 2: Short term stability study of the phosphate buffer formulation stored at 2-8 °C: Tested Initial testing 1 month retest 2 months retest 3 months retest parameters
[0150] Appearance
[0151] Colorless clear Colorless clear Colorless clear Colorless clear Aspect, clarity,
[0152]
[0153] 10337 / PC
[0154] colour solution with a crystal with a crystal with a crystal pH (Ph. Eur. 5.3 5.3 5.3 5.4 2.2.3)
[0155] Osmolality, Not determined Not determined Not determined Diluted 1:1 :
[0156] 640 [mOsmol / kg]* Diluted 1:2 :
[0157] 428 Assay 215 nm215 nm 270 nm270nmEsketamine,
[0158] [mg 147.97 133.30129-7 130-8132.3 Esketamine / g
[0159] solution]
[0160] [% ref. to theo. 98.6 88.9 / 88.8 86.5 87.2 88.2 content]
[0161]
[0162] * Diluted with water
[0163] During storage at 2-8 °C a solid crystal in the solution was observed after 4 weeks. The sample was treated with ultrasound for 10 minutes, where the crystal was slightly reduced in size, but did not completely redissolve. The assay of the solution was determined and compared to the initial value revealing an increase of assay from ~ 89 % to ~95 %. Thus, the esketamine saturation solubility appears to be exceeded when stored at 2- 8 °C.
[0164] The solution stored at 40 °C showed a yellowish discoloration after one month. As no decrease in assay or increase in impurities is evident after one month, either a degradation product may not be detected with the used HPLC method, or the impurity responsible for coloration is below the detection limit of the used method. After two and three months, an increase of impurity B was detected, which can be one reason for the coloration. It is a hydrolysis product of Esketamine. However, literature data indicates that yellowish coloration may occur due to an oxidation product.
[0165] The solution stored at RT did not show any crystallization or discoloration in testing up to 3 months.10337 / PC
[0166] Example 2: Formulation with pH adjustment
[0167] In an attempt to avoid crystallization, increased amount of impurities and yellow discoloration, the formulation of example 1 was adjusted. The buffer concentration was adjusted targeting a pH of the formulation of 4.5. The composition as adjusted is shown in table 3.
[0168] Table 3: Composition of the adjusted formulation (F032-SOL-A-2409-002-01) Substance Content [%]
[0169] Esketamine hydrochloride 17.3
[0170] Disodium hydrogen phosphate, dihydrate 0.181
[0171] Sodium dihydrogen phosphate, dihydrate 1.131
[0172] Sodium hydroxide / HCI ad pH 4.5
[0173] Water for injection ad 100
[0174]
[0175] The formulation was filled into glass vials made of lime / soda glass and stored at 2-8 °C, Room temperature (RT) and 40 °C. Crystallization was observed in the formulation stored at 2-8 °C. It is most probably attributed to overcoming the saturation solubility of the API in the water when decreasing temperature. A yellowish discoloration was observed for the formulation stored at 40°C.
[0176] Example 3: Determining crystallization temperature
[0177] To exclude any effects that can facilitate crystallization such as microbial contamination or particulate matter, the buffer was filtrated through a PES 0.2 pm filter before dissolving the API. To evaluate the influence of pH, two formulations as described in Table 1 and Table 3 were prepared, albeit adjusted to having a pH of 4.5 and 5.3 respectively. They were stored at 2-8 °C, whereby one vial of each formulation was vortexed once per day and the other one was kept standing. After only one day the vortexed vial of both formulations showed small rectangular crystals, whereby larger crystals were found after ~ 48 h of storage at 2- 8 °C in the non-vortexed vial.10337 / PC
[0178] In a further trial, both formulations were filled into glass vials made of borosilicate glass and tempered in a water bath to 10°C or 15 °C, whereby again, one of each formulation was vortexed and one was kept still.
[0179] For 10°C it was seen that vortexing the glass vial increased the crystallization. Further, it was seen that lowering the pH from 5.3 to 4.5 delayed the crystallization. No crystallization was seen after 7 days at 15°C.
[0180] Example 4: Effect of sterile filtration at pH 4.5 in soda lime bulk glasses.
[0181] 3 compositions were prepared as can be seen in table 4.
[0182] One composition contained phosphate buffer with a target pH of 4.5, as this is the preferred buffer. One assumption for the occurrence of crystallization in phosphate buffer might be the precipitation of the Esketamine phosphate salt, which might have a lower solubility. Therefore, one formulation was prepared containing citrate buffer. Coloration might be induced by oxidation, therefore the antioxidant Na-EDTA was added to the composition.
[0183] As furthermore, particulate matter in the APi substance is suspected to facilitate crystallization, all formulations were filtered through a PES syringe filter with a filter surface of 4.9 cm2 and a pore size of 0.22 pm (VWR). Afterwards they were filled into glass vials made of borosilicate glass. A control group with unfiltered phosphate buffer pH 4.5 was prepared, and additionally a filtered phosphate buffer sample was filled into a glass vial which was scratched with a spatula before filling.
[0184] Table 4: Compositions prepared:
[0185] F032-SOL-A- F032-SOL-A-2410- F032-SOL-A-2410- 2409-002-04 003-01 004-01 Phosphate buffer Citrate buffer pH Citrate pH 4.5 4.5 buffer / EDTA pH 4.5 Substance Content [%] Content [%] Content [%]
[0186]
[0187] 10337 / PC
[0188] Esketamine hydrochloride 17.3 17.3 17.3 Disodium hydrogen
[0189] 0.01 - - phosphate, dihydrate
[0190] Sodium hydrogen
[0191] 0.74 - - phosphate, dihydrate
[0192] Citric acid, monohydrate - 1.7 0.23 Disodium-EDTA - - 0.17 Sodium hydroxide Ad pH 4.5 Ad pH 4.5 Ad pH 4.5 Water for injection Ad 100 Ad 100 Ad 100
[0193]
[0194] The compositions were filtered and / or stored according to table 5 where + indicates that the composition was filtered and stored at the relevant temperature, whereas the for F032- SOL-A-2410-003-01 and F032-SOL-A-2410-004-01 under non-filtered indicates that these compositions were not stored in a non-filtered form.
[0195] Table 5: Filtering and storage temperature of the compositions.
[0196] F032-SOL-A-2409- F032-SOL-A-2410- F032-SOL-A-2410- 002-04 003-01 004-01 Phosphate buffer pH Citrate buffer pH 4.5 Citrate buffer / EDTA 4.5 pH 4.5
[0197] Temperature: 2-8 °C 40 °C 2-8 °C 40 °C 2-8 °C 40 °C
[0198] Non-filtered + + - - - -
[0199] Filtered (0.22pm) + a) + + + + +
[0200]
[0201] a) and glass scratched10337 / PC
[0202] It was seen that recrystallisation occurred at 2-8 °C. Lowering pH from 6 or 5.3 to 4.5 with phosphate buffer reduced precipitation, see example 3. In combination with sterile filtration precipitation was further reduced.
[0203] Regarding crystallization, the unfiltered control group crystallized after 2 days at 2-8°C, whereby the filtered phosphate buffer did not crystallize for 8 days. After 9 days, fine rhombic shaped crystals were observed in the vial. The filtered phosphate buffer, which was filled in a glass vial with scratched walls crystallized after 7 days. The citrate buffer and citrate / EDTA formulations showed no crystallization after 14 days.
[0204] Clearly recognizable coloration was observed in phosphate buffer samples stored at 40°C, both filtered and unfiltered after 7 days, whereby citrate and citrate / EDTA samples showed no visible coloration after 14 days.
[0205] Filtration aided in delaying occurrence of crystallization. However, phosphate buffer seemed to lead to faster crystallization than citrate buffer or citrate / EDTA buffer.
[0206] Coloration could be prevented by addition of citrate buffer and citrate / EDTA buffer for 14 days, which strengthens the hypothesis of oxidational reactions. Citrate is also known to possess antioxidative properties.
[0207] When considering crystallization to be a result of exceeding the saturation solubility, different possibilities to optimize the formulation may be considered:
[0208] a. Addition of solubilizers: Polysorbate 80
[0209] b. Addition of crystallization inhibitors: PVP or HPMC
[0210] c. Addition of cosolvents propylene glycole, polyethylene glycole
[0211] Furthermore, the precipitated crystals from a phosphate buffer formulation were isolated, dried, and compared with untreated Esketamin-HCI by FTIR. As it can be seen in Figure 1 no difference in FTIR spectra could be identified, however a transformation into the Esketamin base or the precipitation of a phosphate salt is unlikely to be detected by FTIR.10337 / PC
[0212] Example 5: Formulation optimization with EDTA in primary packaging
[0213] In a further formulation optimization trial, Na-EDTA was added to the phosphate buffer pH 4.5.
[0214] The formulation composition is described in Table 6. Na-EDTA can serve as antioxidant and thus should prevent coloration, considering it originating due to formation of an oxidation product. It may furthermore bind metal ions in the formulation by complexation and thus prevent crystallization.
[0215] For comparison a formulation with phosphate buffer pH 4.5 without NA-EDTA was prepared. The formulation is shown in Table 6.
[0216] Table 6: Composition of formulation F032-SOL-A-2410-005-01 with phosphate buffer pH 4.5 and Na-EDTA and formulation F032-SOL-A-2410-002-05 with phosphate buffer pH 4.5:
[0217] F032-SQL-A-2410-005-01 F032-SQL-A-2410-002-05 Phosphate buffer and Na- Phosphate buffer, pH 4.5 EDTA, pH 4.5
[0218] Substance Content [%] Content [%] Esketamine hydrochloride 17.3 17.3 Disodium hydrogen 0.01 0.01 phosphate, dihydrate
[0219] Sodium dihydrogen 0.90 0.90 phosphate, dihydrate
[0220] Disodium 0.20
[0221] Ethylenediaminetetraacetic
[0222] acid, dihydrate
[0223] Sodium hydroxide / HCI ad pH 4.5 ad pH 4.5 Water for injection ad 100 ad 100
[0224]
[0225] 10337 / PC
[0226] The formulations were filled into the intended primary packaging material: Unit Dose Devices from Aptar. The formulations were thereby filled into a glass vial made of borosilicate glass hydrolytic class I. The device was assembled manually with the assembly kit provided by Aptar.
[0227] The information for the unidose (UDS) Liquid Nasal Spray System (manufacturer Aptar) can be found in Table 7. Each device delivers a single actuation of 100 pL, corresponding to a delivered dose of 15 mg Esketamine.
[0228] Table 7: Information of the unidose Liquid Nasal Spray System
[0229] Type Manufacturer Unitdose System (100 Actuator-ASM / Plunger / Container Aptar, Radolfzell, Germany pg actuation) / Container holder
[0230]
[0231] Both formulations were clear and colorless, an assay with ~ 100 % and no detectable impurities were determined. The delivered dose was for both tested prototypes at 106 % and 110 %, which can be caused due to the filling volume of the vials. Aptar recommends 125 pL filling volume for a delivered dose of 100 pL.
[0232] The vials were tested after being tempered at room temperature for a few hours. The vials were checked for crystals and discoloration after being taken off storage.
[0233] The droplet size distribution was measured via laser diffraction and rather small droplets below 100 pm were detected. The share of droplets below 10 pm is below 10 % for the two tested devices. A representative droplet size distribution is shown in Figure 2 with an actuation force of 40 N, a spray angle of 45° and distance of nozzle and laser beam of 30 mm. The formulations were stored at 2-8 °C, RT and 40 °C as shown in tables 8-13 respectively. After one month the formulation F032-SOL-A-2410-002-05 without EDTA, when stored at 40 °C for 1 month showed a slightly yellow color indicating impurities. The discoloring remained when stored for 2 and 3 months. No discoloring was seen when stored for 3 months at 2-8 °C and RT respectively. The formulation F032-SOL-A-2410-005-01 comprising EDTA showed no discoloration when stored at 2-8 °C, RT and 40 °C for three months.10337 / PC
[0234] Table 8: F032-SOL-A-2410-002-05 with phosphate buffer Aptar vials stored at 2-8 °C (Stability study)
[0235] Tested parameters Initial testing 1 month 2 months 3 months retest retest retest Appearance: Aspect, clarity, Colourless clear Colourless Colourless Colourless colour solution clear clear clear solution solution solution A A A A O O O O
[0236] pH-value 4.48 4.58 4.57 4.55 Assay Esketamine,
[0237] [mg Esketamine / g solution] 151.24 150.04 149.00 151.42 [% ref. to theo. content] 100.8 100.0 99.3 100.9 Esketamine degradation
[0238] impurities, [%]
[0239] Identified impurity A, rel tR 1.6 < 0.1 < 0.1 < 0.1 Identified impurity B, rel tR 3.3 < 0.1 < 0.1 < 0.1 Identified impurity C, rel tR 4.6 < 0.1 < 0.1 < 0.1 Sum of degradation impurities < 0.1 < 0.1 < 0.1 Esketamine delivered dose, 15.90 (corresp.
[0240] [mg / actuation] to 106.0 %)
[0241] Shot weight =
[0242] 104.91 mg
[0243]
[0244] Droplet size distribution, [pm]
[0245] DIO 12.04 11.61 / 12.02 11.59 / 12.11 12.79 / 12.05 D50 31.46 30.66 / 33.72 30.32 / 32.32 34.10 / 31.78
[0246]
[0247] 10337 / PC
[0248] D90 70.36 69.58 / 74.23 66.56 / 68.59 73.27 / 68.28 Fraction <10 pm, [%] 6.27 6.96 / 6.53 7.01 / 6.35 5.51 / 6.34
[0249]
[0250] Table 9 F032-SOL-A-2410-002-05 with phosphate buffer Aptar vials stored at RT (Stability study)
[0251] Tested parameters Initial testing 1 month 2 months 3 months retest retest retest Appearance: Aspect, clarity, Colourless clear Colourless Colourless Colourless colour solution clear clear clear solution solution solution pH-value 4.48 4.60 4.56 4.62 Assay Esketamine,
[0252] [mg Esketamine / g solution] 151.24 150.26 151.75 151.79 [% ref. to theo. content] 100.8 100.2 101.2 101.2 Esketamine degradation
[0253] impurities, [%]
[0254] Unidentified imp., rel. tR 0.77 < 0.05 < 0.1 < 0.1 < 0.1 Identified impurity A, rel tR 1.6 < 0.1 < 0.1 < 0.1 < 0.1 Identified impurity B, rel tR 3.3 < 0.1 < 0.1 < 0.1 < 0.1 Unidentified imp., rel. tR 3.53 < 0.1 < 0.1 < 0.1 < 0.1 Identified impurity C, rel tR 4.6 < 0.1 < 0.1 < 0.1 < 0.1 Sum of degradation impurities < 0.1 < 0.1 < 0.1 < 0.1 Esketamine delivered dose, 15.90 (corresp.
[0255] [mg / actuation] to 106.0 %)
[0256] Shot weight =
[0257]
[0258] 10337 / PC
[0259] 104.91 mg
[0260] Droplet size distribution, [pm]
[0261] DIO 12.04 12.09 / 12.42 12.00 / 14.07 12.13 / 13.77 D50 31.46 33.30 / 32.90 32.10 / 38.57 32.87 / 36.31 D90 70.36 72.69 / 70.55 68.43 / 80.96 70.90 / 75.24 Fraction <10 pm, [%] 6.27 6.40 / 5.90 6.44 / 4.44 6.30 / 4.58
[0262]
[0263] A A A A O O O O
[0264] Table 10: F032-SOL-A-2410-002-05 with phosphate buffer Aptar vials stored at 40 °C (Stability study)
[0265] Tested parameters Initial testing 1 month 2 months 3 months retest retest retest Appearance: Aspect, clarity, Colourless clear Slightly Slightly Yellowish colour solution yellow yellow solution solution solution
[0266] pH-value 4.48 4.39 4.29 4.09 Assay Esketamine,
[0267] [mg Esketamine / g solution] 151.24 149.94 151.70 152.98 [% ref. to theo. content] 100.8 100.0 101.1 102.0 Esketamine degradation
[0268] impurities, [%]
[0269] Unidentified imp., rel. tR 0.56 < 0.1 < 0.1 < 0.1 Unidentified imp., rel. tR 0.77 0.12 < 0.1 < 0.1 Identified impurity A, rel tR 1.6 < 0.1 < 0.1 < 0.1 Identified impurity B, rel tR 3.3 < 0.1 0.11 0.10
[0270]
[0271] 10337 / PC
[0272] Unidentified imp., rel. tR 4.41 < 0.1 < 0.1 < 0.1 < 0.1 Identified impurity C, rel tR 4.6 < 0.1 < 0.1 < 0.1 < 0.1 Unidentified imp., rel. tR 5.33 < 0.1 < 0.1 < 0.1 < 0.1 Unidentified imp., rel. tR 7.21 < 0.1 < 0.1 < 0.1 < 0.1 Sum of degradation impurities < 0.1 0.12 0.11 0.10 Esketamine delivered dose, 15.90 (corresp.
[0273] [mg / actuation] to 106.0 %)
[0274] Shot weight =
[0275] 104.91 mg
[0276] Droplet size distribution, [pm]
[0277] DIO 12.04 12.43 / 12.16 12.98 / 12.16 12.70 / 11.64 D50 31.46 33.64 / 33.08 34.49 / 33.33 33.66 / 33.77 D90 70.36 74.83 / 72.14 73.91 / 73.32 71.87 / 73.64 Fraction <10 pm, [%] 6.27 5.92 / 6.26 5.33 / 6.27 5.61 / 7.14
[0278]
[0279] Table 11: F032-SOL-A-2410-005-01 with phosphate buffer and Na-EDTA Aptar vials stored at 2-8 °C (Stability study)
[0280] Tested parameters Initial testing 1 month 2 months 3 months retest retest retest Appearance: Aspect, clarity, Colourless clear Colourless Colourless Colourless colour solution clear clear clear solution solution solution pH-value 4.50 4.51 4.56 4.51 Assay Esketamine,
[0281]
[0282] 10337 / PC
[0283] [mg Esketamine / g solution] 152.60 150.26 151.26 151.63 [% ref. to theo. content] 101.7 100.2 100.8 101.1 Esketamine degradation
[0284] impurities, [%]
[0285] Identified impurity A, rel tR 1.6 < 0.1 < 0.1 < 0.1 Identified impurity B, rel tR 3.3 < 0.1 < 0.1 < 0.1 Identified impurity C, rel tR 4.6 < 0.1 < 0.1 < 0.1
[0286] A A A A
[0287] Sum of degradation impurities O O O O < 0.1 < 0.1 < 0.1 Esketamine delivered dose, 16.42 (corresp.
[0288] [mg / actuation] to 109.5 %)
[0289] Shot weight =
[0290] 107.97 mg
[0291] Droplet size distribution, [pm]
[0292] DIO 13.41 13.12 / 11.91 11.87 / 12.35 12.10 / 12.92 D50 34.54 34.51 / 32.01 32.26 / 34.11 32.71 / 33.61 D90 72.61 73.59 / 70.22 67.92 / 72.34 70.32 / 71.20 Fraction <10 pm, [%] 4.83 5.10 / 6.56 6.71 / 6.14 6.37 / 5.36
[0293]
[0294] Table 12: F032-SOL-A-2410-005-01 with phosphate buffer and Na-EDTA Aptar vials stored at RT (Stability study)
[0295] Tested parameters Initial testing 1 month 2 months 3 months retest retest retest Appearance: Aspect, clarity, Colourless clear Colourless Colourless Colourless colour solution clear clear clear
[0296]
[0297] 10337 / PC
[0298] solution solution solution pH-value 4.50 4.56 4.58 4.51 Assay Esketamine,
[0299] [mg Esketamine / g solution] 152.60 152.91 152.61 152.71 [% ref. to theo. content] 101.7 101.9 101.7 101.8 Esketamine degradation
[0300] impurities, [%]
[0301] Identified impurity A, rel tR 1.6 A A A A
[0302] O O O O < 0.1 < 0.1 < 0.1 Identified impurity B, rel tR 3.3 < 0.1 < 0.1 < 0.1 Identified impurity C, rel tR 4.6 < 0.1 < 0.1 < 0.1 Sum of degradation impurities < 0.1 < 0.1 < 0.1 Esketamine delivered dose, 16.42 (corresp.
[0303] [mg / actuation] to 109.5 %)
[0304] Shot weight =
[0305] 107.97 mg
[0306] Droplet size distribution, [pm]
[0307] DIO 13.41 13.09 / 12.24 12.87 / 12.39 12.52 / 14.01 D50 34.54 35.06 / 33.22 34.99 / 33.10 33.80 / 37.51 D90 72.61 74.86 / 72.78 75.85 / 70.81 71.49 / 78.40 Fraction <10 pm, [%] 4.83 5.23 / 6.14 5.40 / 5.93 5.84 / 4.42
[0308]
[0309] Table 13 F032-SOL-A-2410-005-01 with phosphate buffer and Na-EDTA Aptar vials stored at 40 °C (Stability study)10337 / PC
[0310] Tested parameters Initial testing 1 month 2 months 3 months retest retest retest Appearance: Aspect, clarity, Colourless clear Colourless Colourless Colourless colour solution clear clear clear solution solution solution pH-value 4.50 4.59 4.57 4.45 Assay Esketamine,
[0311] [mg Esketamine / g solution] 152.60 151.12 153.13 153.88 [% ref. to theo. content] 101.7 100.7 102.1 102.6 Esketamine degradation
[0312] impurities, [%]
[0313] Identified impurity A, rel tR 1.6 < 0.1 < 0.1 < 0.1 < 0.1 Identified impurity B, rel tR 3.3 < 0.1 < 0.1 < 0.1 < 0.1 Identified impurity C, rel tR 4.6 < 0.1 < 0.1 < 0.1 < 0.1 Unidentified imp., rel. tR 5.32 < 0.1 < 0.1 < 0.1 < 0.1 Unidentified imp., rel. tR 7.21 < 0.1 < 0.1 < 0.1 < 0.1 Sum of degradation impurities < 0.1 < 0.1 < 0.1 < 0.1 Esketamine delivered dose, 16.42 (corresp.
[0314] [mg / actuation] to 109.5 %)
[0315] Shot weight =
[0316] 107.97 mg
[0317] Droplet size distribution, [pm]
[0318] DIO 13.41 12.00 / 13.20 12.14 / 12.11 12.72 / 12.05 D50 34.54 32.24 / 35.38 32.97 / 33.16 33.51 / 33.51
[0319]
[0320] 10337 / PC
[0321] D90 72.61 70.92 / 74.28 70.67 / 72.14 69.57 / 73.25 Fraction <10 pm, [%] 4.83 6.45 / 5.13 6.33 / 6.34 5.48 / 6.50
[0322]
[0323] When stored 3 months at 2-8°C or at room temperature (20-25°C), the tested parameters remained almost unchanged for both formulations, within the expected variability of the corresponding testing methods.
[0324] However, when stored at 40°C it could be observed that the degradation impurities of the formulation without EDTA was increased compared to the formulation containing EDTA. It can be consequently assumed that EDTA has a positive impact upon the stability of the formulation.
[0325] Regarding the delivered dose, which was determined initially only (single determination), the higher value determined particularly on the lot F032-SOL-A-2410-005-01, could be related to the filling volume, 125 pl, that was performed manually using a variable piston pipette.
[0326] Example 6: Test of precipitation in containers made of different materials.
[0327] Aptar vials have a volume of 125 pL with a glass quality borosilicate. The precipitation (visually) was compared in 6 Aptar vials and 6 glasses (2 ml bulk) in glass qualities of borosilicate and soda lime respectively. A formulation with esketamine hydrochloride, phosphate buffer, sterile filtration (pore size 0.22 pm) including 0.17% EDTA adjusted to pH 4.5 was used. It was seen that the number of vials with crystals increased faster for the lime soda vials. Very small crystals were observed around the rubber stopper of the Aptar vials after 30 days (3 vials). However, no change in assay was observed after 3 months in Aptar unit dose device indicating a stable formulation with no precipitation, when not stressed by vortexing. It remained a colorless clear solution (see example 5).
[0328] Thus, it appears that borosilicate glass reduces the tendency to precipitation compared to soda lime glass when the composition contains EDTA. Further, using small vials of 125 pL (borosilicate glass) as the Aptar unit dose nasal device appeared to prevent precipitation. Without being bound by theory it may be speculated that the space for recrystallization was10337 / PC
[0329] reduced as no decline in assay was observed after the 3 months when similar samples were tested (see example 5).
[0330] Example 7: Redissolving of API crystals
[0331] Redissolving of API crystals in the containers disclosed in example 6 was assessed. The samples were taken off the fridge and stored at RT. It was seen that for the small Aptar vials a redissolving occurred very quickly, within hours. The larger crystals in the larger glass vials dissolved accordingly slower.
[0332] This confirms that size of the vials / glass matters. After a stability test of 3 months in an Aptar device, at 2-8 C, the very small crystals redissolve within hours at RT. This process of redissolving takes a lot longer for the crystals in the 2 ml vials, as seen in Figures 3 and 4. It appears that only very small crystals are created in the 125 pL vials and their large surface leads to fast redissolving.
Claims
10337 / PCClaims1. A ketamine nasal spray comprising a container, said container comprising a storage stable aqueous solution of ketamine, wherein said aqueous solution of ketamine has a volume of less than 1.0 ml, said aqueous solution of ketamine being obtainable by micro filtration using a filter or membrane having a nominal pore size of less than 0.40 pm; and wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof.
2. The nasal spray according to claim 1, wherein said pharmaceutically acceptable salt is esketamine hydrocholoride.
3. The nasal spray according to any of the preceding claims, wherein said nasal spray allows cooling to 2 - 8 °C without formation of ketamine crystals.
4. The nasal spray according to any of the preceding claims, wherein said nasal spray allows cooling to 2 - 8 °C and storage at a temperature of 2 - 8 °C, and subsequent use at a temperature higher than 10°C without formation of ketamine crystals.
5. The nasal spray according to any of the preceding claims, wherein said solution of ketamine has been adjusted to having a pH of 4.1 - 5.1.
6. The nasal spray according to any of the preceding claims, further comprising EDTA.
7. The nasal spray according to any of the preceding claims, wherein the volume of said aqueous solution of ketamine is selected among 0.01 - 0.99; 0.02 - 0.9; 0.03 - 0.8;10337 / PC0.04 - 0.7; 0.05 - 0.6; 0.06 - 0.5; 0.07 - 0.4; 0.08 - 0.3; 0.09 - 0.2; 0.1 - 0.15; and 0.125 ml, preferably about 0.125 ml.
8. A container for a nasal spray, wherein said container has an inner surface, wherein the part of said inner surface which is in contact with said solution or composition, is made of glass, such as borate or silicate glass.
9. The container according to any of the preceding claims, wherein said container has a volume selected among 0.01 - 2; 0.02 - 1.5; 0.03 - 1.25; 0.04 - 1; 0.05 - 0.75; 0.06 - 0.5; 0.07 - 0.4; 0.08 - 0.3; 0.09 - 0.25; 0.1 - 0.15; and 0.125 ml; preferably about 0.125 ml.
10. The nasal spray according to claim 9, wherein the nasal spray comprises a container, wherein said container is made of borosilicate, borate, silicate glass or soda-lime glass.
11. The nasal spray according to any of the preceding claims, wherein the nasal spray comprises a container, wherein said container has a color, a coating or a surface which protects the solution from light.
12. A method for preparing a storage stable ketamine solution for a nasal spray, wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof, said method comprising:a. Filtration of an aqueous solution of ketamine using a filter or membrane having a nominal pore size of less than 0.40 pm;b. Adjusting the pH, preferably to a pH of 4.1 - 5.1; andc. Filling said aqueous solution in a container for a nasal spray, wherein the volume of said aqueous solution is less than 1.0 ml.10337 / PC13. A method for decreasing the amount of crystallized ketamine or preventing crystallization of ketamine in an aqueous solution in a nasal spray, wherein said ketamine is esketamine (S-ketamine) or a pharmaceutically acceptable salt thereof, wherein said method comprises:a. Filtration of an aqueous solution of ketamine using a filter or membrane having a nominal pore size of less than 0.40 pm;b. Adjusting the pH, preferably to a pH of 4.1 - 5.1; andc. Subsequent storage of said aqueous solution in a container for a nasal spray, wherein the volume of said aqueous solution is less than 1.0 ml.
14. The method according to any of the preceding claims, for manufacturing a nasal spray comprising an aqueous solution of ketamine, wherein said nasal spray allows cooling to a temperature below 10°C and subsequently heating to room temperature before use, to obtain a nasal spray which does not comprise crystallized ketamine after said heating to room temperature.
15. The method according to any of the preceding claims, wherein said nasal spray allows cooling to a temperature in a temperature interval selected among 0 - 10°C, 1 - 9°C, 2 - 8°C, 3 - 7°C, 4 - 6°C, and about 5°C, and subsequently heating to room temperature, such as 20°C, before use, to obtain a nasal spray which does not comprise crystallized ketamine after said heating to room temperature.
16. The method according to any of the preceding claims, wherein said nasal spray allows cooling to a temperature below 10°C and subsequently heating to room temperature, before use, to obtain a nasal spray which does not comprise crystallized ketamine at a time selected among 1 min - 24 hours, preferably 5 min - 20 hours, more preferred 15 min - 16 hours, preferably 30 min - 12 hours, more10337 / PCpreferred 1 - 10 hours, preferably 2 - 8 hours, more preferred 3 - 6 hours, preferably 4 - 5 hours, after said heating to room temperature.
17. The method according to any of the preceding claims, wherein the step of filtration comprises filtration using a filter or membrane having a nominal pore size of 0.01 - 0.39 pm, preferably 0.025 - 0.37 pm, more preferred 0.05 - 0.34 pm, preferably 0.1 - 0.31 pm, more preferred 0.1 - 0.28 pm, preferably 0.2 - 0.25 pm, more preferred 0.22 pm.
18. The method according to any of the preceding claims, wherein the filtration is sterile filtration.
19. The method according to any of the preceding claims, wherein the method prevents crystallization in a temperature interval selected among 0 - 10°C, 1 - 9°C, 2 - 8°C, 3 - 7°C, 4 - 6°C, and preferably about 5°C.
20. The method according to any of the preceding claims, wherein the method prevents crystallization for at least 1 month, more preferred at least 2 months, preferably at least 3 months, more preferred at least 4 months, preferably at least 5 months, more preferred at least 6 months, preferably at least 8 months, more preferred at least 10 months, preferably at least 12 months, more preferred at least 15 months, preferably at least 18 months, more preferred at least 24 months, preferably at least 30 months, more preferred at least 36 months.
21. The method according to any of the preceding claims, wherein the concentration of ketamine is selected among 50 - 200 mg / mL, preferably 75 - 175 mg / mL, more preferred 100 - 150 mg / mL, and preferably about 125 mg / ml.10337 / PC22. The method according to any of the preceding claims, wherein the solution comprises a buffer.
23. The method according to claim 22, wherein the buffer comprises one or more excipients selected among citric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium hydroxide, acetic acid, boric acid, sodium borate, succinic acid, tartaric acid, malic acid, lactic acid, fumaric acid, and the like. Preferably, the buffer or buffer system is selected from the group consisting of sodium hydroxide, citric acid, sodium dihydrogen phosphate and disodium hydrogen phosphate.
24. The method according to claim 22 or 23, wherein the buffer comprises a phosphate buffer.
25. The method according to claim 22 or 23, wherein the buffer comprises a citrate buffer.
26. The method according to any of the preceding claims, wherein the pH is adjusted to an interval selected among 2.5 - 6.5; 2.6 - 6.4; 2.7 - 6.3; 2.8 - 6.2; 2.9 - 6.1; 3.0 - 6.0; 3.1 - 5.9; 3.2 - 5.8; 3.3 - 5.7; 3.4 - 5.6; 3.5 - 5.5; 3.6 - 5.4; 3.7 - 5.3; 3.8 - 5.2; 3.9 - 5.1; 4.0 - 5.0; 4.1 - 4.9; 4.2 - 4.8; 4.3 - 4.7; 4.4 - 4.6; 4.5 - 4.6; and about 4.6.
27. The method according to any of the preceding claims, wherein the pH is adjusted by adding sodium hydroxide and / or hydrochloric acid to the solution.
28. The method according to any of the preceding claims, wherein the solution comprises one or more excipients selected among EDTA and disodium-EDTA.10337 / PC29. The method according to any of the preceding claims, wherein the method comprises a step of filtration of a solution comprising the buffer and / or a solution comprising ketamine.
30. A method for the treatment of cluster headache comprising administration of a solution according to any of the preceding claims, and / or administration using a nasal spray according to any of the preceding claims.
31. A solution or composition obtainable according to any of the preceding claims.
